All Microvention Class III implantable device CE markedAll Microvention Mechanical Thrombectomy Class III device CE marked
All Microvention Class III implantable device CE marked: Endovascular treatment of ruptured or unruptured intracranial aneurysms with commercially available MicroVention implant devices.
All Microvention Mechanical Thrombectomy Class III device CE marked: Endovascular treatment of acute ischemic stroke with commercially available MicroVention devices.
Study summary
The MAESTRO registry is a post-market, single-arm, non-interventional, multicenter registry
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion criteria:
* Patient, or another authorized person as per country-specific regulations, is informed of the data collection and gives non-opposition or consent prior to the data collection in accordance with institutional and geographic requirements.
* For Cohort 1, patient is treated for a ruptured or unruptured intracranial aneurysm using a commercially available MicroVention implant device as the primary treatment device and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study.
* For Cohort 2, patient is treated using a commercially available MicroVention mechanical thrombectomy device as the first-line treatment strategy and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study.
Note: For the purposes of this protocol, ancillary/accessory devices such as balloon catheters, carotid stent for extracranial stenosis and other access devices are not considered primary treatment devices. Further, devices used for rescue following attempt of a different primary treatment device are not considered initial primary treatment devices.
Exclusion Criteria:
* Patient is or is expected to be inaccessible for follow-up.
* Patient is participating or intends to participate in another study that changes the site practice.
* Patient is already participating in the MAESTRO study for the same pathology.
Primary outcome measure(s)
Cohort 1: Proportion of aneurysms with complete occlusion — 18 (±6) months based on Raymond-Roy occlusion classification (RROC) evaluated by an independent Core laboratory
Cohort 2: Proportion of patients achieving final mTICI ≥ 2b revascularization — Mechanical trombectomy Procedure based on independent Corelab assessment
Trial sites (1)
Facility
City
Region
Status
Álvaro Cunqueiro Hospital - University Hospital Complex of Vigo, Department of Radiology
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.